ECSP12011747A - Derivado de anillo heterocíclico fusionado y uso del mismo - Google Patents

Derivado de anillo heterocíclico fusionado y uso del mismo

Info

Publication number
ECSP12011747A
ECSP12011747A ECSP12011747A ECSP12011747A EC SP12011747 A ECSP12011747 A EC SP12011747A EC SP12011747 A ECSP12011747 A EC SP12011747A EC SP12011747 A ECSP12011747 A EC SP12011747A
Authority
EC
Ecuador
Prior art keywords
heterocyclic ring
fused heterocyclic
derivative
same
ring derivative
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Satoshi Sasaki
Yuta Tanaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP12011747A publication Critical patent/ECSP12011747A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ECSP12011747 2009-08-26 2012-03-26 Derivado de anillo heterocíclico fusionado y uso del mismo ECSP12011747A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009195770 2009-08-26
JP2010015644 2010-01-27

Publications (1)

Publication Number Publication Date
ECSP12011747A true ECSP12011747A (es) 2012-05-30

Family

ID=43627972

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011747 ECSP12011747A (es) 2009-08-26 2012-03-26 Derivado de anillo heterocíclico fusionado y uso del mismo

Country Status (24)

Country Link
US (1) US8907089B2 (enExample)
EP (1) EP2471790B1 (enExample)
JP (1) JP5599802B2 (enExample)
KR (1) KR20120078703A (enExample)
CN (1) CN102574851A (enExample)
AU (1) AU2010287492A1 (enExample)
BR (1) BR112012004134A2 (enExample)
CA (1) CA2771833A1 (enExample)
CL (1) CL2012000461A1 (enExample)
CR (1) CR20120095A (enExample)
DO (1) DOP2012000048A (enExample)
EA (1) EA201270311A1 (enExample)
EC (1) ECSP12011747A (enExample)
GE (1) GEP20146075B (enExample)
IL (1) IL218323A0 (enExample)
IN (1) IN2012DN02069A (enExample)
MA (1) MA33589B1 (enExample)
MX (1) MX2012002419A (enExample)
NZ (1) NZ598749A (enExample)
PE (1) PE20121326A1 (enExample)
SG (1) SG178504A1 (enExample)
TN (1) TN2012000084A1 (enExample)
WO (1) WO2011024872A1 (enExample)
ZA (1) ZA201201795B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
WO2002012189A1 (en) 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005081960A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057469A1 (en) * 2006-11-02 2008-05-15 Wyeth Small organic molecule regulators of cell proliferation
CA2690953C (en) 2007-06-29 2012-10-02 Pfizer Inc. Benzimidazole derivatives
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
JP4685891B2 (ja) 2008-02-19 2011-05-18 株式会社ハネックス 分離装置
CN102015705B (zh) * 2008-02-26 2013-11-13 武田药品工业株式会社 稠合的杂环衍生物及其用途
JP2010015644A (ja) 2008-07-04 2010-01-21 Fujitsu Ltd スピンドル機構、電磁変換特性評価機、および情報記憶装置
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent

Also Published As

Publication number Publication date
EA201270311A1 (ru) 2012-09-28
SG178504A1 (en) 2012-04-27
IL218323A0 (en) 2012-04-30
WO2011024872A1 (ja) 2011-03-03
CL2012000461A1 (es) 2012-10-05
TN2012000084A1 (en) 2013-09-19
MA33589B1 (fr) 2012-09-01
US8907089B2 (en) 2014-12-09
ZA201201795B (en) 2013-05-29
BR112012004134A2 (pt) 2017-06-20
EP2471790A1 (en) 2012-07-04
PE20121326A1 (es) 2012-10-11
AU2010287492A1 (en) 2012-03-29
DOP2012000048A (es) 2012-05-15
MX2012002419A (es) 2012-04-19
US20120220570A1 (en) 2012-08-30
NZ598749A (en) 2013-01-25
JP5599802B2 (ja) 2014-10-01
JPWO2011024872A1 (ja) 2013-01-31
EP2471790B1 (en) 2015-03-18
IN2012DN02069A (enExample) 2015-08-21
CR20120095A (es) 2012-06-26
CA2771833A1 (en) 2011-03-03
EP2471790A4 (en) 2013-07-31
CN102574851A (zh) 2012-07-11
GEP20146075B (en) 2014-04-10
KR20120078703A (ko) 2012-07-10

Similar Documents

Publication Publication Date Title
DOP2011000260A (es) Pirimidinas fusionadas
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX2016005394A (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4.
CR20120448A (es) Compuesto heterocíclico
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CR20140537A (es) Compuesto heterocíclico nitrogenado
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX391724B (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2015012386A (es) Inhibidores de la cinasa cdk9.
EA201500931A1 (ru) Производные пиридин-4-ила
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
PH12015500399A1 (en) Azaindolines
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
CR20120095A (es) Derivado de anillo heterocíclico fusionado y uso del mismo
MX345264B (es) Derivado de azol.
AR077843A1 (es) Particulas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato